Home / Home

Sarcoma Research

Sarcoma research emphasizes rare-subtype biology, precision trial design, and targeted/immune approaches across soft-tissue and bone sarcomas.

Our Sarcoma Analysis

  • October 15, 2026Clinical Cancer ResearchBrightline-1 (open-label, randomized phase II/III), NCT05218499

    Brigimadlin Fails to Significantly Improve Progression-Free Survival Over Doxorubicin in Advanced Dedifferentiated Liposarcoma: Phase II/III Brightline-1 Trial

    Brightline-1 randomized patients with MDM2-amplified advanced dedifferentiated liposarcoma to the oral MDM2–p53 antagonist brigimadlin 45 mg or doxorubicin 75 mg/m² every 3 weeks. The primary endpoint, progression-free survival (PFS) by blinded independent central review, was not met: median PFS was 8.4 versus 7.2 months (HR, 0.79; 95% CI, 0.6–1.06; P = 0.0956).

  • September 22, 2026Nature MedicinePATHFINDER 2 (NCT05155605)

    Multi-Cancer Blood Test Reaches 60% Positive Predictive Value and 99.6% Specificity in Largest Prospective Screening Study to Date

    PATHFINDER 2, a prospective, interventional cohort study of 35,878 adults aged 50 and older with no clinical suspicion of cancer, evaluated the performance and safety of a blood-based multi-cancer early detection (MCED) test that analyzes cell-free DNA methylation patterns to detect a shared cancer signal and predict its tissue of origin.

  • August 20, 2026JAMA Oncology

    Industry Now Outpaces Federal Cancer Trial Sponsorship Nearly 5 to 1 — And the Gap Is Widening

    A registry-based analysis of 11,681 US interventional cancer trials registered on ClinicalTrials.gov between 2008 and 2024 found that industry sponsors now outnumber federal sponsors nearly 5 to 1 (4.53-to-1 overall), with the ratio widening from 2.72-to-1 in 2008–2012 to 6.44-to-1 in 2019–2024.

Related topics: Trial Endpoints and Methodology · Fixed-Duration and De-escalated Therapy